Clinical Trials Directory

Trials / Completed

CompletedNCT04873180

Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma

A Retrospective Study

Status
Completed
Phase
Study type
Observational
Enrollment
40 (actual)
Sponsor
Sohag University · Academic / Other
Sex
All
Age
30 Years – 70 Years
Healthy volunteers
Not accepted

Summary

detection of Survivin expression in renal cell carcinoma and correlate this expression to tumor grade and stage.

Detailed description

renal cell carcinoma is the third most prevalent malignant tumor of the genitourinary system. deregulation of apoptosis is involved in carcinogenesis by abnormally prolonged cell survival, facilitating accumulations of multiple mutations and augment resistance to immune-surveillance. Survivin is a member of inhibitor of Apoptosis Protein family (IAPs). it play a role in cell cycle regulation by inhibiting apiptosis. Survivin is over-expressed in many human neoplasms.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTsectioning and staining of renal neoplasms after nephrectomy operationnephrectomy operations will be done to patients diagnosed as having renel tumors

Timeline

Start date
2020-01-01
Primary completion
2020-06-30
Completion
2020-12-30
First posted
2021-05-05
Last updated
2021-05-07

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04873180. Inclusion in this directory is not an endorsement.